文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

初始根治性放疗后前列腺再程放疗采用立体定向体部放疗(SBRT)——近期试验的系统综述与Meta分析

Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy - A systematic review and meta-analysis of recent trials.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-06-20

该系统综述与Meta分析检索2020至2023年发表的14篇文献,评估初始根治性放疗后前列腺癌再程SBRT的安全性及疗效。汇总急性≥2级泌尿生殖毒性和胃肠道毒性分别为13%(95%CI 7-18%)和2%(95%CI 0-4%),晚期≥2级分别为25%(95%CI 14-35%)和5%(95%CI 1-9%),2年生化无复发生存率为72%(95%CI 64-92%)。结论认为再程SBRT安全有效,但需进一步前瞻性数据。

要点

  • 汇总急性≥2级泌尿生殖毒性13%(95%CI 7-18%),胃肠道毒性2%(95%CI 0-4%)。
  • 汇总晚期≥2级泌尿生殖毒性25%(95%CI 14-35%),胃肠道毒性5%(95%CI 1-9%)。
  • 汇总2年生化无复发生存率72%(95%CI 64-92%)。

核心结论

  • SBRT用于放射性复发前列腺癌的再程放疗是安全有效的。
  • 需要进一步的前瞻性数据。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和Embase数据库(2023年10月),发表时间限定2020至2023年,无语种限制,遵循PRISMA推荐。
  • 共纳入14篇出版物。
  • 采用I²检验评估异质性,使用限制性最大似然估计的随机效应模型估计合并效应,通过漏斗图目测和Egger检验评估发表偏倚和/或小研究偏倚。

主要发现

  • 纳入研究报告的急性≥2级泌尿生殖毒性和胃肠道毒性范围分别为0.0-30.0%和0.0-25.0%。
  • 晚期≥2级泌尿生殖毒性和胃肠道毒性范围分别为4.0-51.8%和0.0-25.0%。
  • 汇总急性≥2级泌尿生殖毒性和胃肠道毒性分别为13%(95%CI 7-18%)和2%(95%CI 0-4%)。
  • 汇总晚期≥2级泌尿生殖毒性和胃肠道毒性分别为25%(95%CI 14-35%)和5%(95%CI 1-9%)。
  • 汇总2年生化无复发生存率为72%(95%CI 64-92%)。

关键数值与推荐

  • 纳入研究急性≥2级泌尿生殖毒性范围0.0-30.0%,胃肠道毒性范围0.0-25.0%。
  • 纳入研究晚期≥2级泌尿生殖毒性范围4.0-51.8%,胃肠道毒性范围0.0-25.0%。
  • 汇总急性≥2级泌尿生殖毒性13%(95%CI 7-18%),胃肠道毒性2%(95%CI 0-4%)。
  • 汇总晚期≥2级泌尿生殖毒性25%(95%CI 14-35%),胃肠道毒性5%(95%CI 1-9%)。
  • 汇总2年生化无复发生存率72%(95%CI 64-92%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步的前瞻性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is increasing data on re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after definitive radiotherapy for prostate cancer, with increasing evidence on prostate re-irradiation using a C-arm LINAC or an MR LINAC in recent years. We therefore conducted this systematic review and meta-analysis on prostate re-irradiation including studies published from 2020 to 2023, to serve as an update on existing meta-analysis. METHODS: We searched the PubMed and Embase databases in October 2023 with queries including combinations of "repeat", "radiotherapy", "prostate", "re-irradiation", "reirradiation", "re treatment", "SBRT", "retreatment". Publication date was set to be from 2020 to 2023. There was no limitation regarding language. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. After data extraction, heterogeneity testing was done by calculating the I2. A random effects model with a restricted maximum likelihood estimator was used to estimate the combined effect. Funnel plot asymmetry was assessed visually and using Egger's test to estimate the presence of publication and/or small study bias. RESULTS: 14 publications were included in the systematic review. The rates of acute ≥ grade 2 (G2) genitourinary (GU) and gastrointestinal (GI) toxicities reported in the included studies ranged from 0.0-30.0 % and 0.0-25.0 % respectively. For late ≥ G2 GU and GI toxicity, the ranges are 4.0-51.8 % and 0.0-25.0 %. The pooled rate of acute GU and GI toxicity ≥ G2 were 13 % (95 % CI: 7-18 %) and 2 % (95 % CI: 0-4 %). For late GU and GI toxicity ≥ G2 the pooled rates were 25 % (95 % CI: 14-35 %) and 5 % (95 % CI: 1-9 %). The pooled 2-year biochemical recurrence-free survival was 72 % (95 % CI: 64-92 %). CONCLUSIONS: SBRT in the re-irradiation of radiorecurrent prostate cancer is safe and effective. Further prospective data are warranted.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schröder C, Tang H, Lenffer B, et al. Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy - A systematic review and meta-analysis of recent trials. Clin Transl Radiat Oncol. 2024. PMID: 39044780. doi:10.1016/j.ctro.2024.100806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。